PVCT (Provectus Biopharmaceuticals) Cyclically Adjusted PB Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Provectus Biopharmaceuticals  (OTCPK:PVCT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.85 7.88 15.99 0.00 0.00

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PVCT vs PSTV, ALGS, ATNM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Provectus Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Provectus Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.016/330.2130*330.2130
=-0.016

Current CPI (Mar. 2026) = 330.2130.

Provectus Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.043 241.018 0.059
201609 0.022 241.428 0.030
201612 0.010 241.432 0.014
201703 -0.002 243.801 -0.003
201706 -0.011 244.955 -0.015
201709 -0.020 246.819 -0.027
201712 -0.027 246.524 -0.036
201803 -0.033 249.554 -0.044
201806 -0.036 251.989 -0.047
201809 -0.040 252.439 -0.052
201812 -0.045 251.233 -0.059
201903 -0.049 254.202 -0.064
201906 -0.054 256.143 -0.070
201909 -0.058 256.759 -0.075
201912 -0.062 256.974 -0.080
202003 -0.066 258.115 -0.084
202006 -0.070 257.797 -0.090
202009 -0.072 260.280 -0.091
202012 -0.076 260.474 -0.096
202103 -0.078 264.877 -0.097
202106 -0.007 271.696 -0.009
202109 -0.007 274.310 -0.008
202112 -0.010 278.802 -0.012
202203 -0.012 287.504 -0.014
202206 -0.015 296.311 -0.017
202209 -0.016 296.808 -0.018
202212 -0.015 296.797 -0.017
202303 -0.017 301.836 -0.019
202306 -0.017 305.109 -0.018
202309 -0.018 307.789 -0.019
202312 -0.018 306.746 -0.019
202403 -0.018 312.332 -0.019
202406 -0.018 314.175 -0.019
202409 -0.013 315.301 -0.014
202412 -0.014 315.605 -0.015
202503 -0.012 319.799 -0.012
202506 -0.014 322.561 -0.014
202509 -0.015 324.800 -0.015
202512 -0.015 324.054 -0.015
202603 -0.016 330.213 -0.016

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.